Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Autogene cevumeran |
Synonyms | |
Therapy Description |
Autogene cevumeran (RO7198457) is a personalized neoantigen-specific immunotherapy that stimulates T-cell mediated immune response against tumor cells, potentially resulting in antitumor activity (PMID: 37165196). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Autogene cevumeran | RG 6180|RG-6180|RG6180|RO-7198457|RO 7198457|RO7198457|BNT 122|BNT-122|BNT122 | Autogene cevumeran (RO7198457) is a personalized neoantigen-specific immunotherapy that stimulates T-cell mediated immune response against tumor cells, potentially resulting in antitumor activity (PMID: 37165196). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04486378 | Phase II | Autogene cevumeran | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Recruiting | USA | SWE | GBR | ESP | DEU | BEL | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |